Protocol Ledger

NCT07188610 · Phase II · RECRUITING

PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

Interventional Phase II clinical trial protocol NCT07188610 sponsored by PersonGen BioTherapeutics (Suzhou) Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-09-25 Enrollment: 100 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07188610
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07188610
Protocol FieldVerified Registry Value
NCT IdentifierNCT07188610
Consolidated Lead SponsorPersonGen BioTherapeutics (Suzhou) Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment100 participants (ESTIMATED)
Registered Start Date2025-09-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI